Ocugen, Inc. (OCGN)
OCGN Stock Price Chart
Explore Ocugen, Inc. interactive price chart. Choose custom timeframes to analyze OCGN price movements and trends.
OCGN Company Profile
Discover essential business fundamentals and corporate details for Ocugen, Inc. (OCGN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
3 Dec 2014
Employees
95.00
Website
https://www.ocugen.comCEO
Shankar Musunuri
Description
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
OCGN Financial Timeline
Browse a chronological timeline of Ocugen, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 7 May 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.06.
Earnings released on 1 Aug 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $1.37M , beating expectations by +357.67%.
Earnings released on 9 May 2025
EPS came in at -$0.05 surpassing the estimated -$0.06 by +16.67%, while revenue for the quarter reached $1.48M .
Earnings released on 5 Mar 2025
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $764.00K , beating expectations by +91.00%.
Earnings released on 14 Nov 2024
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $1.14M , beating expectations by +278.67%.
Earnings released on 8 Aug 2024
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $1.14M .
Earnings released on 16 Apr 2024
EPS came in at -$0.04 surpassing the estimated -$0.06 by +33.33%, while revenue for the quarter reached $1.01M .
Earnings released on 26 Mar 2024
EPS came in at -$0.03 surpassing the estimated -$0.06 by +50.00%, while revenue for the quarter reached $6.04M .
Earnings released on 9 Nov 2023
EPS came in at -$0.06 surpassing the estimated -$0.08 by +25.00%.
Earnings released on 21 Aug 2023
EPS came in at -$0.10 falling short of the estimated -$0.08 by -25.00%.
Earnings released on 5 May 2023
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%, while revenue for the quarter reached $443.00K .
Earnings released on 28 Feb 2023
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%.
Earnings released on 8 Nov 2022
EPS came in at -$0.10 matching the estimated -$0.10.
Earnings released on 5 Aug 2022
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%.
Earnings released on 6 May 2022
EPS came in at -$0.09 falling short of the estimated $0.05 by -280.00%.
Earnings released on 25 Feb 2022
EPS came in at -$0.07 matching the estimated -$0.07.
Earnings released on 9 Nov 2021
EPS came in at -$0.05 falling short of the estimated -$0.04 by -25.00%.
Earnings released on 6 Aug 2021
EPS came in at -$0.13 falling short of the estimated -$0.03 by -333.33%.
Earnings released on 7 May 2021
EPS came in at -$0.04 falling short of the estimated $0.50 by -108.00%.
Earnings released on 18 Mar 2021
EPS came in at -$0.03 falling short of the estimated -$0.02 by -50.00%, while revenue for the quarter reached $42.58M .
Earnings released on 6 Nov 2020
EPS came in at -$0.07 falling short of the estimated -$0.02 by -250.00%.
OCGN Stock Performance
Access detailed OCGN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.